Spyre Therapeutics, Inc.SYRENASDAQ
Loading
Year-over-year total asset growth rate
5Y CAGR
+69.7%/yr
Long-term compound
Percentile
P85
Within normal range
vs 5Y Ago
14.1x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 54.14% |
| Q3 2025 | -6.35% |
| Q2 2025 | -5.43% |
| Q1 2025 | -6.36% |
| Q4 2024 | 44.50% |
| Q3 2024 | -3.43% |
| Q2 2024 | -10.57% |
| Q1 2024 | 42.63% |
| Q4 2023 | 64.94% |
| Q3 2023 | -14.89% |
| Q2 2023 | 364.28% |
| Q1 2023 | -26.27% |
| Q4 2022 | -22.30% |
| Q3 2022 | -14.19% |
| Q2 2022 | 28.30% |
| Q1 2022 | -24.34% |
| Q4 2021 | -14.83% |
| Q3 2021 | -12.19% |
| Q2 2021 | -10.17% |
| Q1 2021 | 1.24% |
| Q4 2020 | 3.85% |
| Q3 2020 | -9.99% |
| Q2 2020 | 166.92% |
| Q1 2020 | -22.12% |
| Q4 2019 | -16.90% |
| Q3 2019 | -14.81% |
| Q2 2019 | -8.58% |
| Q1 2019 | 65.32% |
| Q4 2018 | 9.07% |
| Q3 2018 | -10.58% |
| Q2 2018 | 60.11% |
| Q1 2018 | -11.22% |
| Q4 2017 | -7.31% |
| Q3 2017 | -9.89% |
| Q2 2017 | 9.59% |
| Q1 2017 | -8.64% |
| Q4 2016 | -6.94% |
| Q3 2016 | -6.78% |
| Q2 2016 | 117.49% |
| Q1 2016 | -8.05% |